Compare Merck & Co., Inc. (MRK) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Petróleo Brasileiro SA — how do they compare? Merck & Co., Inc. trades at $132.58 (market cap $321.77B), while Petróleo Brasileiro SA trades at $17.9 (market cap $112.19B). The key difference: Merck & Co., Inc. is far larger — about 2.9× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.42%). Which is the better fit depends on your goals.
| MRK | PBR | |
|---|---|---|
Market Cap | $321.77B | $112.19B |
Sector | Health | Technology |
52-Week High | $131.84 | $22.03 |
52-Week Low | $77.60 | $11.54 |
Enterprise Value | $368.53B | $172.61B |
Dividend Yield | 2.61% | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Petrobras (PBR) trades at $17.93, down 2.18% today, showing strong fundamentals with a P/E of 4.53 and robust profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $1.60 versus $1.40 expected, driven by record production and higher oil prices. Technical indicators signal bearish momentum, with RSI at oversold levels near 20.31, while analyst consensus remains positive with 50% buy ratings.
The outlook remains favorable due to cheap valuations and production growth, but risks include regulatory uncertainty and volatile oil prices. Investment opportunity lies in sustained dividend payments and operational efficiency, though geopolitical and macroeconomic factors could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
